{"entity":{"id":"rejuv-trial-ex-cipn","kind":"trial","name":"EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage","aka":["EX-CIPN","NCT07481149"],"tldr":"Nothing prevents chemotherapy nerve damage and the only drug with guideline support for the established painful form has a benefit the guideline itself calls limited. This pragmatic trial tests ten weeks of individualised remote exercise against usual care.","summary":"The nerve-damage record on this front states the position the trial is built against: ASCO recommends no agent for the prevention of chemotherapy-induced peripheral neuropathy, duloxetine is the only agent with appropriate evidence for established painful neuropathy and the guideline says the amount of benefit is limited, and a long list of other candidates has failed or has no reliable evidence. Scrambler therapy's only blinded comparison found the dummy device did as well.\n\nEX-CIPN is a pragmatic, parallel-group, two-arm randomised controlled trial of a ten-week programme: an individualised progressive exercise prescription including cardiovascular and strength training plus balance and desensitisation work specific to neuropathy symptoms, remote monitoring with an activity tracker, and health coaching calls in weeks 2, 3, 4, 6 and 8. The control arm receives usual oncology care and is offered the programme after completing study assessments. Masking covers the care provider and the outcomes assessor.\n\nThe primary endpoint is the EORTC CIPN-20 questionnaire, scored 20 to 80 with higher scores worse, measured at baseline, at the end of the ten weeks, and at three and six months afterwards. That a phase 3 trial in this condition is using a symptom questionnaire rather than nerve conduction is itself informative about where the field's endpoints stand.\n\nRegistry dates, read on 2 October 2026: start 30 March 2026 (actual), primary completion and completion July 2029 (estimated). Enrolment of 240 is the registry's estimate.","status":"recruiting","asOf":"2026-10-02","links":[{"label":"ClinicalTrials.gov NCT07481149","url":"https://clinicaltrials.gov/study/NCT07481149"},{"label":"Loprinzi et al., Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update (JCO 2020)","url":"https://doi.org/10.1200/JCO.20.01399"}],"tags":["rejuvenation","survivorship","open-problem","neuropathy","rehabilitation","exercise"],"related":["cipn-recovery-and-treatment","scrambler-therapy","rejuv-agenda-rehabilitation-not-commissioned","rejuv-agenda-nothing-restores-cognition","exercise-prescription-after-cancer","idea-moon-neuropathy-prevention-programme","rejuvenation-roadmap"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07481149","phase":"3","setting":"Adults with persistent chemotherapy-induced peripheral neuropathy after treatment, Canada","sponsor":"University Health Network, Toronto","started":"2026-03-30","startedType":"actual","enrolled":240,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/rejuv-trial-ex-cipn/","neighbours":{"technology":[{"id":"cipn-recovery-and-treatment","kind":"technology","name":"Nerve damage from chemotherapy: what recovers, and what helps","route":"/technologies/cipn-recovery-and-treatment/"},{"id":"scrambler-therapy","kind":"technology","name":"Scrambler therapy (Calmare) for chemotherapy nerve pain","route":"/technologies/scrambler-therapy/"},{"id":"exercise-prescription-after-cancer","kind":"technology","name":"The exercise prescription after cancer: the dose the guidelines state","route":"/technologies/exercise-prescription-after-cancer/"}],"bottleneck":[{"id":"rejuv-agenda-nothing-restores-cognition","kind":"bottleneck","name":"No treatment restores the thinking that cancer treatment takes","route":"/bottlenecks/rejuv-agenda-nothing-restores-cognition/"},{"id":"rejuv-agenda-rehabilitation-not-commissioned","kind":"bottleneck","name":"Rehabilitation is recommended everywhere and commissioned almost nowhere","route":"/bottlenecks/rejuv-agenda-rehabilitation-not-commissioned/"}],"idea":[{"id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/"}],"roadmap":[{"id":"rejuvenation-roadmap","kind":"roadmap","name":"Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it","route":"/roadmaps/rejuvenation-roadmap/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}]}}